Clinical Trial Update: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies [Phase 1]

View source ↗

Summary

Phase 1 trial update exploring pembrolizumab in combination with an autologous dendritic cell vaccine for PD-L1-negative malignant mesothelioma in patients who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Mesothelioma, Malignant, PD-L1 Negative | Phase 1 | Status: ACTIVE_NOT_RECRUITING